## Frank Edelmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9288966/publications.pdf

Version: 2024-02-01

100 papers 6,567 citations

34 h-index 77 g-index

102 all docs

 $\begin{array}{c} 102 \\ \\ \text{docs citations} \end{array}$ 

102 times ranked 7617 citing authors

#	Article	IF	CITATIONS
1	Movement therapy in lung transplantation candidates assisted by a lightweight wearable robot. Assistive Technology, 2023, 35, 242-247.	2.0	1
2	Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages. Clinical Research in Cardiology, 2023, 112, 868-879.	3.3	4
3	Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial. Clinical Research in Cardiology, 2022, 111, 308-321.	3.3	10
4	NTâ€proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials. ESC Heart Failure, 2022, 9, 100-109.	3.1	13
5	Biomarkerâ€based assessment of collagen crossâ€linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <scp>HOMAGE</scp> clinical trial. European Journal of Heart Failure, 2022, 24, 321-331.	7.1	16
6	Left atrial strain predicts exercise capacity in heart failure independently of left ventricular ejection fraction. ESC Heart Failure, 2022, 9, 842-852.	3.1	17
7	Movement therapy in advanced heart failure assisted by a lightweight wearable robot: a feasibility pilot study. ESC Heart Failure, 2022, 9, 1643-1650.	3.1	5
8	Discordance between estimated and measured changes in plasma volume among patients with acute heart failure. ESC Heart Failure, 2022, 9, 66-76.	3.1	7
9	Peak O <sub>2</sub> â€pulse predicts exercise trainingâ€induced changes in peak V̇O <sub>2</sub> in heart failure with preserved ejection fraction. ESC Heart Failure, 2022, 9, 3393-3406.	3.1	3
10	Improving exercise capacity and quality of life using nonâ€invasive heart failure treatments: evidence from clinical trials. European Journal of Heart Failure, 2021, 23, 92-113.	7.1	67
11	Left atrial function and maximal exercise capacity in heart failure with preserved and midâ€range ejection fraction. ESC Heart Failure, 2021, 8, 116-128.	3.1	21
12	OUTSTEPâ€HF: randomised controlled trial comparing shortâ€term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 127-135.	7.1	50
13	Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 325, 542.	7.4	144
14	The diagnostic and prognostic value of galectinâ€3 in patients at risk for heart failure with preserved ejection fraction: results from the DIASTâ€CHF study. ESC Heart Failure, 2021, 8, 829-841.	3.1	24
15	Myocardial deformation assessed among heart failure entities by cardiovascular magnetic resonance imaging. ESC Heart Failure, 2021, 8, 890-897.	3.1	10
16	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	3.0	4
17	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277.	4.1	46
18	Performance of a cardiac lipid panel compared to four prognostic scores in chronic heart failure. Scientific Reports, 2021, 11, 8164.	3.3	4

#	Article	IF	CITATIONS
19	Serum creatinine and cystatin Câ€based estimates of glomerular filtration rate are misleading in acute heart failure. ESC Heart Failure, 2021, 8, 3070-3081.	3.1	11
20	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event. JAMA Cardiology, 2021, 6, 706.	6.1	53
21	Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 1633-1644.	7.1	26
22	Lipid Metabolite Biomarkers in Cardiovascular Disease: Discovery and Biomechanism Translation from Human Studies. Metabolites, 2021, 11, 621.	2.9	26
23	miR-181c level predicts response to exercise training in patients with heart failure and preserved ejection fraction: an analysis of the OptimEx-Clin trial. European Journal of Preventive Cardiology, 2021, 28, 1722-1733.	1.8	14
24	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart †OMics†in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696.	2.2	77
25	Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial. Cells, 2021, 10, 2796.	4.1	3
26	Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 1919.	7.4	72
27	Iron Deficiency Impacts Diastolic Function, Aerobic Exercise Capacity, and Patient Phenotyping in Heart Failure With Preserved Ejection Fraction: A Subanalysis of the OptimEx-Clin Study. Frontiers in Physiology, 2021, 12, 757268.	2.8	7
28	Higher galectin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure. BioPsychoSocial Medicine, 2020, 14, 24.	2.1	0
29	Incremental prognostic value of a novel metaboliteâ€based biomarker score in congestive heart failure patients. ESC Heart Failure, 2020, 7, 3029-3039.	3.1	6
30	Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. BMC Cardiovascular Disorders, 2020, 20, 408.	1.7	26
31	A Random Shuffle Method to Expand a Narrow Dataset and Overcome the Associated Challenges in a Clinical Study: A Heart Failure Cohort Example. Frontiers in Cardiovascular Medicine, 2020, 7, 599923.	2.4	4
32	Rationale and study design of <scp>OUTSTEPâ€HF</scp> : a randomised controlled study to assess the effect of sacubitril/valsartan and enalapril on physical activity measured by accelerometry in patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1724-1733.	7.1	8
33	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2020, 22, 391-412.	7.1	193
34	Variability of Myocardial Strain During Isometric Exercise in Subjects With and Without Heart Failure. Frontiers in Cardiovascular Medicine, 2020, 7, 111.	2.4	13
35	Economic impact of heart failure with preserved ejection fraction: insights from the ALDOâ€DHF trial. ESC Heart Failure, 2020, 7, 786-793.	3.1	6
36	Inferior vena cavaÂultrasound in acute decompensated heart failure: design rationale of the <scp>CAVAâ€ADHFâ€DZHK10</scp> trial. ESC Heart Failure, 2020, 7, 973-983.	3.1	17

#	Article	IF	CITATIONS
37	Syncopes and clinical outcome in heart failure: results from prospective clinical study data in Germany. ESC Heart Failure, 2020, 7, 942-952.	3.1	4
38	Predictive value of metabolomic biomarkers for cardiovascular disease risk: a systematic review and meta-analysis. Biomarkers, 2020, 25, 101-111.	1.9	24
39	Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction. Cardiac Failure Review, 2020, 6, 1-7.	3.0	8
40	Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fraction. IJC Heart and Vasculature, 2020, 28, 100525.	1.1	3
41	CMR Tissue Characterization in Patients with HFmrEF. Journal of Clinical Medicine, 2019, 8, 1877.	2.4	26
42	Range Variability in CMR Feature Tracking Multilayer Strain across Different Stages of Heart Failure. Scientific Reports, 2019, 9, 16478.	3.3	20
43	How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2019, 40, 3297-3317.	2.2	944
44	Higher plasma levels of CT-proAVP are linked to less anxiety in men but not women with cardiovascular risk factors: Results from the observational Diast-CHF study. Psychoneuroendocrinology, 2019, 101, 272-277.	2.7	5
45	Morbidity and mortality in patients with cardiovascular risk factors and obstructive sleep apnoea: results from the DIAST-CHF cohort. Respiratory Medicine, 2019, 154, 127-132.	2.9	17
46	Heterogeneous Metabolic Response to Exercise Training in Heart Failure with Preserved Ejection Fraction. Journal of Clinical Medicine, 2019, 8, 591.	2.4	4
47	Exercise training in patients with a left ventricular assist device (Exâ€VAD): rationale and design of a multicentre, prospective, assessorâ€blinded, randomized, controlled trial. European Journal of Heart Failure, 2019, 21, 1152-1159.	7.1	19
48	Motivational interviewing can support physical activity in elderly patients with diastolic heart failure: results from a pilot study. ESC Heart Failure, 2019, 6, 658-666.	3.1	9
49	Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction. ESC Heart Failure, 2019, 6, 262-270.	3.1	28
50	Diastolic stress test echocardiography in patients with suspected heart failure with preserved ejection fraction: a pilot study. ESC Heart Failure, 2019, 6, 146-153.	3.1	32
51	Anti- szlig 1-Adrenoreceptor auto-Antibodies in elderly heart failure patients. Frontiers in Bioscience - Landmark, 2019, 24, 1037-1049.	3.0	2
52	Prognostic performance of serial inâ€hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the <scp>MOLITOR</scp> study. ESC Heart Failure, 2018, 5, 288-296.	3.1	26
53	Biomarkerâ€based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldoâ€DHF trial. European Journal of Heart Failure, 2018, 20, 1290-1299.	7.1	64
54	Investigating a biomarkerâ€driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum Câ€terminal propeptide of procollagen type I (DROPâ€PIP trial). European Journal of Heart Failure, 2018, 20, 460-470.	7.1	29

#	Article	IF	CITATIONS
55	Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction. ESC Heart Failure, 2018, 5, 53-62.	3.1	19
56	Potential Usefulness and Clinical RelevanceÂof Adding Left Atrial Strain to LeftÂAtrialÂVolume Index in the Detection of Left Ventricular Diastolic Dysfunction. JACC: Cardiovascular Imaging, 2018, 11, 1405-1415.	5.3	215
57	Lower limit of normality and clinical relevance of left ventricular early diastolic strain rate for the detection of left ventricular diastolic dysfunction. European Heart Journal Cardiovascular Imaging, 2018, 19, 905-915.	1.2	22
58	Chronic Heart Failure. Deutsches A& #x0308; rzteblatt International, 2018, 115, 124-130.	0.9	22
59	Rationale and design of a multicentre, randomized, placeboâ€controlled trial of mirabegron, a Beta3â€adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3â€left ventricular hypertrophy (Beta3â€LVH). ESC Heart Failure, 2018, 5, 830-841.	3.1	29
60	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC: Heart Failure, 2018, 6, 874-883.	4.1	159
61	Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet, The, 2018, 392, 1047-1057.	13.7	467
62	Early detection of cardiac alterations by left atrial strain in patients with risk for cardiac abnormalities with preserved left ventricular systolic and diastolic function. International Journal of Cardiovascular Imaging, 2018, 34, 701-711.	1.5	13
63	Normal range and usefulness of right ventricular systolic strain to detect subtle right ventricular systolic abnormalities in patients with heart failure: a multicentre study. European Heart Journal Cardiovascular Imaging, 2017, 18, 212-223.	1.2	126
64	Arterial stiffness and elevated left ventricular filling pressure in patients at risk for the development or a previous diagnosis of HF—A subgroup analysis from the DIAST-CHF study. Journal of the American Society of Hypertension, 2017, 11, 303-313.	2.3	18
65	Prognostic impact of diastolic dysfunction in systolic heart failure—A crossâ€project analysis from the German Competence Network Heart Failure. Clinical Cardiology, 2017, 40, 667-673.	1.8	13
66	Exercise training in Diastolic Heart Failure (Exâ€≺scp>DHF): rationale and design of a multicentre, prospective, randomized, controlled, parallel group trial. European Journal of Heart Failure, 2017, 19, 1067-1074.	7.1	37
67	Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. Open Heart, 2017, 4, e000630.	2.3	72
68	Estimating fat mass in heart failure patients. Archives of Medical Sciences Atherosclerotic Diseases, 2016, 1, 78-89.	1.0	1
69	Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression. JAMA - Journal of the American Medical Association, 2016, 315, 2683.	7.4	226
70	Clinical Relevance of Left Atrial Strain to Predict Recurrence of Atrial Fibrillation after Catheter Ablation: A Metaâ€Analysis. Echocardiography, 2016, 33, 724-733.	0.9	40
71	NT-proBNP and diastolic left ventricular function in patients with Marfan syndrome. IJC Heart and Vasculature, 2016, 12, 15-20.	1.1	7
72	Poor self-rated health predicts mortality in patients with stable chronic heart failure. European Journal of Cardiovascular Nursing, 2016, 15, 504-512.	0.9	16

#	Article	IF	Citations
73	Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF. JACC: Heart Failure, 2016, 4, 140-149.	4.1	49
74	Elevated Plasma C-Terminal Endothelin-1 Precursor Fragment Concentrations Are Associated with Less Anxiety in Patients with Cardiovascular Risk Factors. Results from the Observational DIAST-CHF Study. PLoS ONE, 2015, 10, e0136739.	2.5	5
75	Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. Journal of Applied Physiology, 2015, 119, 1233-1242.	2.5	104
76	Higher plasma levels of MR-pro-atrial natriuretic peptide are linked to less anxiety: results from the observational DIAST-CHF study. Clinical Research in Cardiology, 2015, 104, 574-581.	3.3	18
77	Should procalcitonin be measured routinely in acute decompensated heart failure?. Biomarkers in Medicine, 2015, 9, 651-659.	1.4	13
78	Galectinâ€3 in patients with heart failure with preserved ejection fraction: results from the Aldoâ€ <scp>DHF</scp> trial. European Journal of Heart Failure, 2015, 17, 214-223.	7.1	146
79	Plasma mid-regional pro-adrenomedullin levels are inversely associated with anxiety but unrelated to depression: Results from the observational DIAST-CHF study in patients with cardiovascular risk factors. Psychoneuroendocrinology, 2015, 62, 227-232.	2.7	9
80	Natriuretic peptides for the detection of paroxysmal atrial fibrillation. Open Heart, 2015, 2, e000182.	2.3	23
81	Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. European Journal of Preventive Cardiology, 2015, 22, 582-593.	1.8	85
82	Associations of Methylarginines and Homoarginine With Diastolic Dysfunction and Cardiovascular Risk Factors in Patients With Preserved Left Ventricular Ejection Fraction. Journal of Cardiac Failure, 2014, 20, 923-930.	1.7	35
83	Effects of longâ€ŧerm endurance and resistance training on diastolic function, exercise capacity, and quality of life in asymptomatic diastolic dysfunction vs. heart failure with preserved ejection fraction. ESC Heart Failure, 2014, 1, 59-74.	3.1	19
84	Diagnosis of Heart Failure with Preserved Ejection Fraction. Heart Failure Clinics, 2014, 10, 399-406.	2.1	20
85	New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. European Heart Journal, 2014, 35, 2797-2815.	2.2	304
86	Utilization of galectin-3 in case management across the spectrum of heart failure. Reviews in Cardiovascular Medicine, 2014, 15, 197-207.	1.4	0
87	Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction — Results of the Aldo-DHF trial. International Journal of Cardiology, 2013, 169, 408-417.	1.7	34
88	Galectinâ€3 in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2013, 15, 1095-1101.	7.1	90
89	Determinants of Change in Quality of Life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD). European Journal of Internal Medicine, 2013, 24, 333-338.	2.2	14
90	Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2013, 309, 781.	7.4	604

#	Article	IF	CITATION
91	Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. European Heart Journal, 2012, 33, 203-212.	2.2	<b>7</b> 5
92	Exercise Training Improves Exercise Capacity and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2011, 58, 1780-1791.	2.8	564
93	Impaired physical quality of life in patients with diastolic dysfunction associates more strongly with neurohumoral activation than with echocardiographic parameters. American Heart Journal, 2011, 161, 797-804.	2.7	36
94	Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clinical Research in Cardiology, 2011, 100, 755-764.	3.3	101
95	Heart failure therapy in diabetic patients- comparison with the recent ESC/EASD guideline. Cardiovascular Diabetology, 2011, 10, 15.	6.8	5
96	Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. European Journal of Heart Failure, 2011, 13, 670-680.	7.1	157
97	The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. European Journal of Heart Failure, 2010, 12, 1309-1316.	7.1	123
98	A network against failing heartsâ€"Introducing the German "Competence Network Heart Failure― International Journal of Cardiology, 2010, 145, 135-138.	1.7	39
99	Rationale and design of the †aldosterone receptor blockade in diastolic heart failure' trial: a doubleâ€blind, randomized, placeboâ€controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomatic diastolic heart failure (Aldoâ€DHF). European Journal of Heart Failure. 2010. 12, 874-882.	7.1	67
100	Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clinical Research in Cardiology, 2008, 97, 578-586.	3.3	50